2 results
Approved WMORecruiting
1) To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus those receiving placebo plus pembrolizumab
Approved WMOCompleted
The purpose of this study is to determine the safety and efficacy of AMG 334 compared to placebo in episodic migraine patients who havepreviously failed 2 to 4 prophylactic migraine treatments and therefore have a high unmet medical need.